As a classic target of anticancer treatments, EGFR is commonly overexpressed in different carcinomas, exerting a crucial role in the pathogenesis and progression of in diverse cancers such as non‐small cell lung cancer (NSCLC).[11, 12] Chemical inhibitors of EGFR have been adopted as the first‐line therapy of EGFR‐mutant NSCLC. Here, EGFR is linked to cancer.